Non-viral causes of liver cancer: Does obesity led inflammation play a role?

Cancer Letters

Volumn 345, Issue 2, 2014, Pages 223-229

  Alzahrani, Badr ^a   Iseli, Tristan J ^a   Hebbard, Lionel W ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Inflammation; Liver cancer; Obesity

Indexed keywords

ADIPONECTIN; AFLATOXIN; ANTIBIOTIC AGENT; FATTY ACID; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LEPTIN; METFORMIN; PITAVASTATIN; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; BONE DISEASE; CANCER PREVENTION; CYTOKINE RELEASE; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; INSULIN RESISTANCE; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OSTEOLYSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK REDUCTION; SHORT SURVEY; SIGNAL TRANSDUCTION; WEIGHT REDUCTION;

HEPACIVIRUS;

INFLAMMATION; LIVER CANCER; OBESITY;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; FATTY LIVER; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LIVER NEOPLASMS; OBESITY; PROGNOSIS; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84896727640     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.08.036     Document Type: Review

References (100)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics. CA Cancer J. Clin. 2002, 55(2005):74-108.
2. Fan J.G., Farrell G.C. Prevention of hepatocellular carcinoma in nonviral-related liver diseases. J. Gastroenterol. Hepatol. 2009, 24:712-719.
3. Blonski W., Kotlyar D.S., Forde K.A. Non-viral causes of hepatocellular carcinoma. World J. Gastroenterol. 2010, 16:3603-3615.
4. Moller H., Mellemgaard A., Lindvig K., Olsen J.H. Obesity and cancer risk: a Danish record-linkage study. Eur. J. Cancer 1994, 30A:344-350.
5. Polesel J., Zucchetto A., Montella M., Dal Maso L., Crispo A., La Vecchia C., Serraino D., Franceschi S., Talamini R. The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. Ann. Oncol. 2009, 20:353-357.
6. Calle E.E., Rodriguez C., Walker-Thurmond K., Thun M.J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med. 2003, 348:1625-1638.
7. Welzel T.M., Graubard B.I., Zeuzem S., El-Serag H.B., Davila J.A., McGlynn K.A. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-medicare database. Hepatology 2011, 54:463-471.
8. Chen C.L., Yang H.I., Yang W.S., Liu C.J., Chen P.J., You S.L., Wang L.Y., Sun C.A., Lu S.N., Chen D.S., Chen C.J. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 2008, 135:111-121.
9. Brunt E.M., Janney C.G., Di Bisceglie A.M., Neuschwander-Tetri B.A., Bacon B.R. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 1999, 94:2467-2474.
10. Day C.P., Saksena S. Non-alcoholic steatohepatitis: definitions and pathogenesis. J. Gastroenterol. Hepatol. 2002, 17(Suppl. 3):S377-384.
11. Marra F., Gastaldelli A., Svegliati Baroni G., Tell G., Tiribelli C. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol. Med. 2008, 14:72-81.
12. Hebbard L., George J. Animal models of nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 2011, 8:35-44.
13. Holzer Ryan G., Park E.-J., Li N., Tran H., Chen M., Choi C., Solinas G., Karin M. Saturated fatty acids induce c-Src clustering within membrane subdomains, leading to JNK activation. Cell 2011, 147:173-184.
14. Solinas G., Naugler W., Galimi F., Lee M.S., Karin M. Saturated fatty acids inhibit induction of insulin gene transcription by JNK-mediated phosphorylation of insulin-receptor substrates. PNAS 2006, 103:16454-16459.
15. Solinas G., Vilcu C., Neels J.G., Bandyopadhyay G.K., Luo J.-L., Naugler W., Grivennikov S., Wynshaw-Boris A., Scadeng M., Olefsky J.M., Karin M. JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity. Cell Metab. 2007, 6:386-397.
16. Fukata M., Abreu M.T. Role of Toll-like receptors in gastrointestinal malignancies. Oncogene 2008, 27:234-243.
17. Berasain C., Castillo J., Perugorria M.J., Latasa M.U., Prieto J., Avila M.A. Inflammation and liver cancer: new molecular links. Ann. N.Y. Acad. Sci. 2009, 1155:206-221.
18. He G., Karin M. NF-kappaB and STAT3 - key players in liver inflammation and cancer. Cell Res. 2011, 21:159-168.
19. Nakagawa H., Maeda S. Inflammation- and stress-related signaling pathways in hepatocarcinogenesis. World J. Gastroenterol. 2012, 18:4071-4081.
20. Maeda S., Kamata H., Luo J.L., Leffert H., Karin M. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 2005, 121:977-990.
21. Sakurai T., Maeda S., Chang L., Karin M. Loss of hepatic NF-κB activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. PNAS 2006, 103:10544-10551.
22. Hirosumi J., Tuncman G., Chang L., Gorgun C.Z., Uysal K.T., Maeda K., Karin M., Hotamisligil G.S. A central role for JNK in obesity and insulin resistance. Nature 2002, 420:333-336.
23. Schattenberg J.M., Singh R., Wang Y., Lefkowitch J.H., Rigoli R.M., Scherer P.E., Czaja M.J. Jnk1 but not jnk2 promotes the development of steatohepatitis in mice. Hepatology 2006, 43:163-172.
24. Luedde T., Beraza N., Kotsikoris V., van Loo G., Nenci A., De Vos R., Roskams T., Trautwein C., Pasparakis M. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 2007, 11:119-132.
25. Tomita K., Tamiya G., Ando S., Ohsumi K., Chiyo T., Mizutani A., Kitamura N., Toda K., Kaneko T., Horie Y., Han J.-Y., Kato S., Shimoda M., Oike Y., Tomizawa M., Makino S., Ohkura T., Saito H., Kumagai N., Nagata H., Ishii H., Hibi T. Tumour necrosis factor α signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut 2006, 55:415-424.
26. Knight B., Yeoh G.C., Husk K.L., Ly T., Abraham L.J., Yu C., Rhim J.A., Fausto N. Impaired preneoplastic changes and liver tumor formation in tumor necrosis factor receptor type 1 knockout mice. J. Exp. Med. 2000, 192:1809-1818.
27. Siddique A., Kowdley K.V. Insulin resistance and other metabolic risk factors in the pathogenesis of hepatocellular carcinoma. Clin. Liver Dis. 2011, 15:281-296. (vii-x).
28. Naugler W.E., Karin M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol. Med. 2008, 14:109-119.
29. He G., Yu G.Y., Temkin V., Ogata H., Kuntzen C., Sakurai T., Sieghart W., Peck-Radosavljevic M., Leffert H.L., Karin M. Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell 2010, 17:286-297.
30. Malaguarnera M., Di Fazio I., Laurino A., Romeo M., Giugno I., Trovato B. Role of interleukin 6 in hepatocellular carcinoma. Bull. Cancer 1996, 83:379-384.
31. Maione D., Di Carlo E., Li W., Musiani P., Modesti A., Peters M., Rose-John S., Della Rocca C., Tripodi M., Lazzaro D., Taub R., Savino R., Ciliberto G. Coexpression of IL-6 and soluble IL-6R causes nodular regenerative hyperplasia and adenomas of the liver. EMBO J. 1998, 17:5588-5597.
32. Bosch F.X., Ribes J., Díaz M., Cléries R. Primary liver cancer: Worldwide incidence and trends. Gastroenterology 2004, 127:S5-S16.
33. 2 couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 2005, 121:977-990.
34. Naugler W.E., Sakurai T., Kim S., Maeda S., Kim K., Elsharkawy A.M., Karin M. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007, 317:121-124.
35. Yu L.X., Yan H.X., Liu Q., Yang W., Wu H.P., Dong W., Tang L., Lin Y., He Y.Q., Zou S.S., Wang C., Zhang H.L., Cao G.W., Wu M.C., Wang H.Y. Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents. Hepatology 2010, 52:1322-1333.
36. Dapito D.H., Mencin A., Gwak G.Y., Pradere J.P., Jang M.K., Mederacke I., Caviglia J.M., Khiabanian H., Adeyemi A., Bataller R., Lefkowitch J.H., Bower M., Friedman R., Sartor R.B., Rabadan R., Schwabe R.F. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 2012, 21:504-516.
37. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
38. Lin H., Yan J., Wang Z., Hua F., Yu J., Sun W., Li K., Liu H., Yang H., Lv Q., Xue J., Hu Z.W. Loss of immunity-supported senescence enhances susceptibility to hepatocellular carcinogenesis and progression in Toll-like receptor 2-deficient mice. Hepatology 2013, 57:171-182.
39. Minmin S., Xiaoqian X., Hao C., Baiyong S., Xiaxing D., Junjie X., Xi Z., Jianquan Z., Songyao J. Single nucleotide polymorphisms of Toll-like receptor 4 decrease the risk of development of hepatocellular carcinoma. PloS One 2011, 6:e19466.
40. Schröder N.W., Schumann R.R. Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet Infect. Dis. 2005, 5:156-164.
41. Cottrell E., Mercer J. Leptin receptors. Appetite Control 2012, 3-21. Springer, Berlin, Heidelberg. H.-G. Joost (Ed.).
42. Carbone F., La Rocca C., Matarese G. Immunological functions of leptin and adiponectin. Biochimie 2012, 94:2082-2088.
43. Ikejima K., Honda H., Yoshikawa M., Hirose M., Kitamura T., Takei Y., Sato N. Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals. Hepatology 2001, 34:288-297.
44. 2-dependant MAPK pathways. J. Biol. Chem. 2004, 279:4292-4304.
45. 2-dependent MAPK pathways. J. Cell Biochem. 2006, 97:188-197.
46. Chitturi S., Farrell G., Frost L., Kriketos A., Lin R., Liddle C., Samarasinghe D., George J. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity?. Hepatology 2002, 36:403-409.
47. Angulo P., Alba L.M., Petrovic L.M., Adams L.A., Lindor K.D., Jensen M.D. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J. Hepatol. 2004, 41:943-949.
48. Wang Y.Y., Lin S. Leptin in relation to hepatocellular carcinoma in patients with liver cirrhosis. Horm. Res. Paediatr. 2003, 60:9.
49. Sadik N.A.H., Ahmed A., Ahmed S. The significance of serum levels of adiponectin, leptin, and hyaluronic acid in hepatocellular carcinoma of cirrhotic and noncirrhotic patients. Hum. Exp. Toxicol. 2012, 31:311-321.
50. Sierra-Honigmann M.R.o., Nath A.K., Murakami C., García-Cardeña G., Papapetropoulos A., Sessa W.C., Madge L.A., Schechner J.S., Schwabb M.B., Polverini P.J., Flores-Riveros J.R. Biological action of leptin as an angiogenic factor. Science 1998, 281:1683-1686.
51. Kitade M., Yoshiji H., Kojima H., Ikenaka Y., Noguchi R., Kaji K., Yoshii J., Yanase K., Namisaki T., Asada K., Yamazaki M., Tsujimoto T., Akahane T., Uemura M., Fukui H. Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats. Hepatology 2006, 44:983-991.
52. Ribatti D., Belloni A.S., Nico B., Di Comite M., Crivellato E., Vacca A. Leptin-leptin receptor are involved in angiogenesis in human hepatocellular carcinoma. Peptides 2008, 29:1596-1602.
53. Saxena N.K., Sharma D., Ding X., Lin S., Marra F., Merlin D., Anania F.A. Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res. 2007, 67:2497-2507.
54. Scherer P.E., Williams S., Fogliano M., Baldini G., Lodish H.F. A novel serum protein similar to C1q, produced exclusively in adipocytes. J. Biol. Chem. 1995, 270:26746-26749.
55. Wolf A.M., Wolf D., Rumpold H., Enrich B., Tilg H. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem. Biophys. Res. Commun. 2004, 323:630-635.
56. Berg A.H., Combs T.P., Scherer P.E. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol. Metab. 2002, 13:84-89.
57. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J., Hotta K., Shimomura I., Nakamura T., Miyaoka K., Kuriyama H., Nishida M., Yamashita S., Okubo K., Matsubara K., Muraguchi M., Ohmoto Y., Funahashi T., Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 1999, 257:79-83.
58. Kubota N., Terauchi Y., Yamauchi T., Kubota T., Moroi M., Matsui J., Eto K., Yamashita T., Kamon J., Satoh H., Yano W., Froguel P., Nagai R., Kimura S., Kadowaki T., Noda T. Disruption of adiponectin causes insulin resistance and neointimal formation. J. Biol. Chem. 2002, 277:25863-25866.
59. Okamoto Y., Kihara S., Ouchi N., Nishida M., Arita Y., Kumada M., Ohashi K., Sakai N., Shimomura I., Kobayashi H., Terasaka N., Inaba T., Funahashi T., Matsuzawa Y. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002, 106:2767-2770.
60. Yuan J., Liu W., Liu Z.L., Li N. CDNA cloning, genomic structure, chromosomal mapping and expression analysis of ADIPOQ (adiponectin) in chicken. Cytogenet. Genome Res. 2006, 112:148-151.
61. Wang Y., Lam K.S., Yau M.H., Xu A. Post-translational modifications of adiponectin: mechanisms and functional implications. Biochem. J. 2008, 409:623-633.
62. Pajvani U.B., Hawkins M., Combs T.P., Rajala M.W., Doebber T., Berger J.P., Wagner J.A., Wu M., Knopps A., Xiang A.H., Utzschneider K.M., Kahn S.E., Olefsky J.M., Buchanan T.A., Scherer P.E. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J. Biol. Chem. 2004, 279:12152-12162.
63. Hug C., Wang J., Ahmad N.S., Bogan J.S., Tsao T.-S., Lodish H.F. T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. PNAS 2004, 101:10308-10313.
64. Kadowaki T., Yamauchi T., Kubota N., Hara K., Ueki K., Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J. Clin. Invest. 2006, 116:1784-1792.
65. Goldstein B.J., Scalia R. Adiponectin: a novel adipokine linking adipocytes and vascular function. J. Clin. Endocrinol. Metab. 2004, 89:2563-2568.
66. Kadowaki T., Yamauchi T. Adiponectin and adiponectin receptors. Endocrine Rev. 2005, 26:439-451.
67. Khetani S.R., Chen A.A., Ranscht B., Bhatia S.N. T-cadherin modulates hepatocyte functions in vitro. The FASEB J. 2008, 22:3768-3775.
68. Yamauchi T., Kamon J., Ito Y., Tsuchida A., Yokomizo T., Kita S., Sugiyama T., Miyagishi M., Hara K., Tsunoda M., Murakami K., Ohteki T., Uchida S., Takekawa S., Waki H., Tsuno N.H., Shibata Y., Terauchi Y., Froguel P., Tobe K., Koyasu S., Taira K., Kitamura T., Shimizu T., Nagai R., Kadowaki T. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003, 423:762-769.
69. Horton J.D. Sterol regulatory element-binding proteins: transcriptional activators of lipid synthesis. Biochem. Soc. Trans. 2002, 30:1091-1095.
70. Ouchi N., Kihara S., Arita Y., Okamoto Y., Maeda K., Kuriyama H., Hotta K., Nishida M., Takahashi M., Muraguchi M., Ohmoto Y., Nakamura T., Yamashita S., Funahashi T., Matsuzawa Y. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000, 102:1296-1301.
71. Kobashi C., Urakaze M., Kishida M., Kibayashi E., Kobayashi H., Kihara S., Funahashi T., Takata M., Temaru R., Sato A., Yamazaki K., Nakamura N., Kobayashi M. Adiponectin inhibits endothelial synthesis of interleukin-8. Circ. Res. 2005, 97:1245-1252.
72. Yokota T., Oritani K., Takahashi I., Ishikawa J., Matsuyama A., Ouchi N., Kihara S., Funahashi T., Tenner A.J., Tomiyama Y., Matsuzawa Y. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000, 96:1723-1732.
73. Hui J.M., Hodge A., Farrell G.C., Kench J.G., Kriketos A., George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin?. Hepatology 2004, 40:46-54.
74. Jarrar M.H., Baranova A., Collantes R., Ranard B., Stepanova M., Bennett C., Fang Y., Elariny H., Goodman Z., Chandhoke V., Younossi Z.M. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol. Ther. 2008, 27:412-421.
75. Kaser S., Moschen A., Cayon A., Kaser A., Crespo J., Pons-Romero F., Ebenbichler C.F., Patsch J.R., Tilg H. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 2005, 54:117-121.
76. Musso G., Gambino R., Biroli G., Carello M., Faga E., Pacini G., De Michieli F., Cassader M., Durazzo M., Rizzetto M., Pagano G. Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic Beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 2005, 100:2438-2446.
77. Asano T., Watanabe K., Kubota N., Gunji T., Omata M., Kadowaki T., Ohnishi S. Adiponectin knockout mice on high fat diet develop fibrosing steatohepatitis. J. Gastroenterol. Hepatol. 2009, 24:1669-1676.
78. Kamada Y., Tamura S., Kiso S., Matsumoto H., Saji Y., Yoshida Y., Fukui K., Maeda N., Nishizawa H., Nagaretani H., Okamoto Y., Kihara S., Miyagawa J., Shinomura Y., Funahashi T., Matsuzawa Y. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 2003, 125:1796-1807.
79. Zhou M., Xu A., Tam P.K.H., Lam K.S.L., Chan L., Hoo R.L.C., Liu J., Chow K.H.M., Wang Y. Mitochondrial dysfunction contributes to the increased vulnerabilities of adiponectin knockout mice to liver injury. Hepatology 2008, 48:1087-1096.
80. Masaki T., Chiba S., Tatsukawa H., Yasuda T., Noguchi H., Seike M., Yoshimatsu H. Adiponectin protects LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese mice. Hepatology 2004, 40:177-184.
81. Xu A., Wang Y., Keshaw H., Xu L.Y., Lam K.S., Cooper G.J. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J. Clin. Invest. 2003, 112:91-100.
82. Liu C.J., Chen P.J., Lai M.Y., Liu C.H., Chen C.L., Kao J.H., Chen D.S. High serum adiponectin correlates with advanced liver disease in patients with chronic hepatitis B virus infection. Hepatol. Int. 2009, 3:364-370.
83. Chen M.J., Yeh Y.T., Lee K.T., Tsai C.J., Lee H.H., Wang S.N. The promoting effect of adiponectin in hepatocellular carcinoma. J. Surg. Oncol. 2012, 106:181-187.
84. Tacke F., Wustefeld T., Horn R., Luedde T., Srinivas Rao A., Manns M.P., Trautwein C., Brabant G. High adiponectin in chronic liver disease and cholestasis suggests biliary route of adiponectin excretion in vivo. J. Hepatol. 2005, 42:666-673.
85. Tietge U.J., Boker K.H., Manns M.P., Bahr M.J. Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics. Am. J. Physiol. Endocrinol. Metab. 2004, 287:E82-89.
86. van der Poorten D., Samer C.F., Ramezani-Moghadam M., Coulter S., Kacevska M., Schrijnders D., Wu L.E., McLeod D., Bugianesi E., Komuta M., Roskams T., Liddle C., Hebbard L., George J. Hepatic fat loss in advanced nonalcoholic steatohepatitis: are alterations in serum adiponectin the cause. Hepatology 2012.
87. Kamada Y., Matsumoto H., Tamura S., Fukushima J., Kiso S., Fukui K., Igura T., Maeda N., Kihara S., Funahashi T., Matsuzawa Y., Shimomura I., Hayashi N. Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model. J. Hepatol. 2007, 47:556-564.
88. Saxena N.K., Fu P.P., Nagalingam A., Wang J., Handy J., Cohen C., Tighiouart M., Sharma D., Anania F.A. Adiponectin modulates C-jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma. Gastroenterology 2010, 139:1762-1773. e1761-e1765.
89. Man K., Ng K.T., Xu A., Cheng Q., Lo C.M., Xiao J.W., Sun B.S., Lim Z.X., Cheung J.S., Wu E.X., Sun C.K., Poon R.T., Fan S.T. Suppression of liver tumor growth and metastasis by adiponectin in nude mice through inhibition of tumor angiogenesis and downregulation of Rho kinase/IFN-inducible protein 10/matrix metalloproteinase 9 signaling. Clin. Cancer Res. 2010, 16:967-977.
90. Kirk G.D., Bah E., Montesano R. Molecular epidemiology of human liver cancer: insights into etiology, pathogenesis and prevention from the Gambia, West Africa. Carcinogenesis 2006, 27:2070-2082.
91. Lasky T., Magder L. Hepatocellular carcinoma p53 G>T transversions at codon 249: the fingerprint of aflatoxin exposure?. Environ. Health Perspect. 1997, 105:392-397.
92. Bressac B., Kew M., Wands J., Ozturk M. Selective G-T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991, 350:429-431.
93. Ming L., Thorgeirsson S.S., Gail M.H., Lu P., Harris C.C., Wang N., Shao Y., Wu Z., Liu G., Wang X., Sun Z. Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology 2002, 36:1214-1220.
94. Yu M.C., Yuan J.-M. Environmental factors and risk for hepatocellular carcinoma. Gastroenterology 2004, 127:S72-S78.
95. Mahady S.E., George J. Management of nonalcoholic steatohepatitis: an evidence-based approach. Clin. Liver Dis. 2012, 16:631-645.
96. Lai S.-W., Chen P.-C., Liao K.-F., Muo C.-H., Lin C.-C., Sung F.-C. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. Am. J. Gastroenterol. 2012, 107:46-52.
97. Donadon V., Balbi M., Mas M.D., Casarin P., Zanette G. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int. 2010, 30:750-758.
98. Bhalla K., Hwang B.J., Dewi R.E., Twaddel W., Goloubeva O.G., Wong K.-K., Saxena N.K., Biswal S., Girnun G.D. Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis. Cancer Prev. Res. 2012, 5:544-552.
99. El-Serag H.B., Johnson M.L., Hachem C., Morgana R.O. Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology 2009, 136:1601-1608.
100. Shimizu M., Yasuda Y., Sakai H., Kubota M., Terakura D., Baba A., Ohno T., Kochi T., Tsurumi H., Tanaka T., Moriwaki H. Pitavastatin suppresses diethylnitrosamine-induced liver preneoplasms in male C57BL/KsJ-db/db obese mice. BMC Cancer 2011, 11:281.